1.
|
The appointment of Dr Harry (Hal) Dietz was made by the Board on the recommendation of the Nominations & Corporate Governance Committee.
| |
2.
|
The Board has determined that Dr Hal Dietz will be an independent Non-Executive Director on appointment in accordance with the UK Corporate Governance Code.
| |
3.
|
Dr Hal Dietz will receive the standard basic fee for a Non-Executive Director of £95,000 per annum. He will also receive a further £30,000 in respect of his additional duties as a Board Scientific and Medical Expert and a one-off fee of £40,000 as the independent Chair of GSK's Human Genetics Scientific Advisory Board.
Dr Hal Dietz will be required to invest at least 25% of his fees in GSK shares that should be held until his retirement from the Board.
| |
4. |
"Scientific and Medical Expert" - The Board designates Non-Executive Directors whose expertise or backgrounds as renowned medical scientists, researchers, or physicians mean that they can bring scientific or industry expertise to the Board's deliberations.
| |
5.
|
Membership of other Committees will be determined in due course.
| |
6.
|
Dr Hal Dietz does not have a service contract. He has a letter of appointment which may be viewed by contacting the Company Secretary at the Company's registered office.
| |
7.
|
There are no additional details to disclose in respect of Dr Hal Dietz's appointment under Listing Rule 9.6.13R.
| |
8.
|
From 1 January 2022 the Board of GSK will comprise:
| |
Sir Jonathan Symonds
Emma Walmsley
Iain Mackay
Dr Hal Barron
Vindi Banga
Charles Bancroft
Dr Anne Beal
Dr Vivienne Cox
Dr Hal Dietz
Lynn Elsenhans
Dr Jesse Goodman
Dr Laurie Glimcher
Urs Rohner
|
Non-Executive Chairman
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer and President, R&D
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
|
GSK enquiries:
| |||
Media enquiries:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
| |
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
| |
Analyst/Investor enquiries:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
| |
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
| |
Mick Readey
|
+44 (0) 7990 339653
|
(London)
| |
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
| |
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Attachments
- Original document
- Permalink
Disclaimer
GSK - GlaxoSmithKline plc published this content on 27 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2021 10:57:12 UTC.